Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) said Friday the European Commission has given market authorization for its closely-watched diabetes treatment Victoza in the 27 European ...

A month's supply of a 10mg maintenance dose is priced at around R4 600. Liraglutide is marketed by Novo Nordisk in three formulations: Saxenda, Victoza, and Xultophy. All three products, which are ...

Novo Nordisk A/S NVO reported fourth-quarter 2024 ... and recorded sales of DKK 6.9 billion for the quarter, up 18%. Victoza sales declined 22% during the reported quarter. Obesity Care (Saxenda ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...